‘Prolor’ Reports Positive Results In Obesity Drug Trial

Prolor Biotech reported positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate MOD-6030. During the trial, the drug was administered to diet-induced obese mice once weekly over a 30-day period. According to Prolor, the results demonstrated efficacy in reducing weight, lowering blood glucose levels, increasing insulin sensitivity and reducing cholesterol levels as compared to a group that received placebo.